The domestic GPGPU manufacturer Iluvatar CoreX (09903.HK) announced the completion of a new H-share placement on July 13, issuing a total of 14.857 million shares at HKD 476 per share, raising net proceeds of approximately HKD 7.034 billion. This comes only about half a year after the company's initial listing on the Hong Kong stock exchange at the beginning of the year and a mere month after its official inclusion in the Hong Kong Stock Connect scheme on June 8. The substantial, high-frequency fundraising pace, coupled with a placement discount of nearly 20%, has drawn market attention to its cash burn rate and the associated risk of future dilution.
Placement Discount and Share Dilution
This placement was managed by Goldman Sachs and Morgan Stanley as joint bookrunners, with J.P. Morgan acting as a passive joint participant. It was successfully placed to no fewer than six independent institutional investors at a final price of HKD 476 per share. In terms of pricing, the placement price represents a 15% discount to the closing price of HKD 560 on the trading day preceding the announcement and an approximately 19.42% discount to the average price over the prior five trading days. This discount level is on the higher side among recent placements for Hong Kong-listed technology stocks.
Regarding the impact on share capital, the placement shares account for about 6.06% of the company's total issued H-shares and approximately 5.52% of the total enlarged share capital, making the dilution from a single round not extreme. However, it is noteworthy that this placement utilized only 29.21% of the general mandate granted at the company's annual general meeting. Over 70% of the authorized capacity remains, theoretically allowing for further share issuance in the short term.
The company has concurrently committed not to undertake any further share issuances within 90 days after the settlement date without consent, temporarily locking in supply-side pressure. However, once this 90-day moratorium ends, if capital expenditure demands in the industry continue to rise, the possibility of the company utilizing the remaining authorized capacity for further fundraising cannot be ruled out, requiring investors to be vigilant about ongoing dilution risks.
Persistent Losses and Cash Flow Strain
Financial data shows that while Iluvatar CoreX has experienced rapid revenue growth in recent years, profitability remains under significant pressure. In 2025, the company achieved operating revenue of RMB 1.034 billion, representing a substantial year-on-year increase of 91.58%. However, it reported a net loss of RMB 1.004 billion for the full year, a 12.46% widening compared to the 2024 loss. The absolute scale of the loss still exceeded its revenue for the period, indicating it has not yet moved beyond the heavy investment phase.
The pressure on cash flow is even more pronounced. In 2025, the company's net cash outflow from operating activities was RMB 1.162 billion, significantly higher than the net loss figure, reflecting the strain on working capital from factors like supply chain inventory buildup and customer payment terms. As of the end of 2025, the company's cash and cash equivalents on the balance sheet stood at approximately RMB 1.505 billion. If measured against the 2025 operating cash outflow rate, the lack of self-sustaining cash generation capability results in an extremely high reliance on external financing.
The company acknowledged in its placement announcement that by the end of May 2026, over 70% of the proceeds allocated for working capital and general corporate purposes from the global offering had already been utilized. The procurement pressure on the supply chain driven by the explosion in AI computing demand has exceeded expectations at the time of the IPO. This explains why a large-scale follow-on financing was initiated only half a year after listing—the IPO proceeds are being depleted faster than anticipated.
Strategic Focus on Supply Chain Inventory
The allocation of the raised funds is also noteworthy. Of the HKD 7.034 billion net proceeds, approximately HKD 4.22 billion (60%) is earmarked for strategic supply chain resilience and procurement planning for key materials and components. This is intended to secure the supply of critical parts such as memory, wafers, substrates, and packaging materials and to establish buffer inventories. Fifteen percent is allocated for product iteration and next-generation R&D; 10% is directed towards the full-stack software platform and developer ecosystem; 10% is reserved for strategic investments and acquisitions; and the remaining 5% will supplement working capital.
The company attributes the core rationale for this substantial fundraising to the supercharged development of the AI industry: a surge in demand for AI training and inference clusters since early 2026 has led to tight global supply and significant price volatility for key components like memory, with upstream suppliers generally requiring longer-term procurement planning and inventory buffers. This logic holds merit during an industry upcycle but also harbors inherent risks.
On one hand, the semiconductor industry is notably cyclical, and there is uncertainty regarding the sustainability of the current high demand for AI computing power. If industry demand experiences a cyclical downturn, key components stockpiled at high prices could face impairment risks. On the other hand, after committing substantial funds to inventory, the company's flexibility for long-term investments in R&D and ecosystem development will be constrained. Should supply chain tightness ease, the cost-effectiveness of the stockpiling strategy could quickly diminish.
Valuation Considerations Post-Placement
Iluvatar CoreX's inclusion in the Hong Kong Stock Connect on June 8, 2026, and the resulting liquidity premium from southbound capital inflows objectively created a more favorable market window for the company to launch the placement.
On the business front, the company launched its Tongyang series of edge-side computing products in the first half of the year and is developing rack-scale super-node products, expanding from chip-level to system-level offerings and continuously broadening its product portfolio. However, competition in the GPGPU sector is intensifying, with accelerated iterations from international players and the entry of domestic peers, creating uncertainty around both technological roadmaps and commercial deployment. Although gross margins remain above 50%, the revenue scale is still insufficient to cover the high R&D and operational expenditures, and the break-even point remains distant.
Overall, this placement significantly strengthens Iluvatar CoreX's cash reserves, providing ammunition for supply chain preparation and product iteration. However, it also highlights the capital-intensive nature and rapid cash burn characteristic of the AI chip sector. For investors, the focus should extend beyond whether the company can capture the industry红利 from the AI computing demand boom. It must also include vigilance regarding the triple risks of potential continued share issuance and dilution, the ability of its inventory strategy to navigate industry cycles, and whether the pace of commercial deployment can keep up with the high investment tempo.
Comments